Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting
Sarah Sharman Moser,1 Lior Apter,1,2 Idit Livnat,3 Roni Ginsburg,3 Adva Yarden,3 Michal Drori,1 Anat Drizon,1 Gabriel Chodick,1,4 Nava Siegelmann-Danieli1,4 1Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, Tel Aviv, Israel; 2Department of Health Systems Mana...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2024-03-01
|
| Series: | Breast Cancer: Targets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/clinical-outcomes-of-patients-with-her2-positive-metastatic-breast-can-peer-reviewed-fulltext-article-BCTT |
| _version_ | 1797269828998791168 |
|---|---|
| author | Sharman Moser S Apter L Livnat I Ginsburg R Yarden A Drori M Drizon A Chodick G Siegelmann-Danieli N |
| author_facet | Sharman Moser S Apter L Livnat I Ginsburg R Yarden A Drori M Drizon A Chodick G Siegelmann-Danieli N |
| author_sort | Sharman Moser S |
| collection | DOAJ |
| description | Sarah Sharman Moser,1 Lior Apter,1,2 Idit Livnat,3 Roni Ginsburg,3 Adva Yarden,3 Michal Drori,1 Anat Drizon,1 Gabriel Chodick,1,4 Nava Siegelmann-Danieli1,4 1Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, Tel Aviv, Israel; 2Department of Health Systems Management, Ben-Gurion University of the Negev, Beer-Sheva, Israel; 3Medical Affairs, AstraZeneca, Kefar Sava, Israel; 4Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelCorrespondence: Sarah Sharman Moser, Email moser_sa@mac.org.ilBackground: In this observational study, we analyzed the treatment patterns and clinical outcomes of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) who developed brain metastases during their disease in a 2.7 million-member public health-provider in Israel.Methods: Newly diagnosed patients with mBC who initiated first-line treatment between January 2013 and June 2021 were identified. Time on treatment (ToT) and overall survival (OS) were assessed at a minimum of 6 months follow-up (cutoff: December 2021).Results: We identified a total of 61 patients: 98.4% females, median age 50 years (IQR = 44– 63), 85% invasive ductal tumors, 44% hormone receptor positive, 51% performance status 0– 1. The median duration of follow-up was 6.2 years. All patients initiated a combination treatment of trastuzumab, pertuzumab, and chemotherapy (TPC), and 72% moved to second-line treatment during the study follow-up period (82% ado-trastuzumab emtansine). The median ToT for first-line and second-line treatments were 16.9 months (95% CI = 13.9– 27.7) and 7.9 months (95% CI = 5.6– 10.9), respectively. The median overall survival (OS) was 45.5 months (95% CI = 35.4– 71.2) from the initiation of first-line treatment. When considering the timing of brain metastases, the median OS was 36.3 months (95% CI = 10.0–NR) for those diagnosed upfront (n = 15, 25%), 59.1 months (95% CI = 32.5–NR) for those diagnosed while on TPC (n = 25, 41%), and 40.8 months (95% CI = 35.4–NR) for those diagnosed at a later stage (n = 21, 34%). The median OS from brain metastases diagnosis was 25.1 months (95% CI = 17.0– 34.6).Conclusion: Patients with upfront brain involvement at the time of mBC diagnosis had shorter survival compared to those who started TPC without brain metastases. Nonetheless, the overall results from this study compare favorably with previous studies and contribute to understanding the value of traditional treatment options, which will serve as a baseline for future treatment strategies in the real-world setting.Keywords: HER2 positive, metastatic, breast cancer, observational study, real-world |
| first_indexed | 2024-04-25T01:54:35Z |
| format | Article |
| id | doaj.art-c21389342c9b4542adf350af1acbe4b7 |
| institution | Directory Open Access Journal |
| issn | 1179-1314 |
| language | English |
| last_indexed | 2024-04-25T01:54:35Z |
| publishDate | 2024-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Breast Cancer: Targets and Therapy |
| spelling | doaj.art-c21389342c9b4542adf350af1acbe4b72024-03-07T17:38:47ZengDove Medical PressBreast Cancer: Targets and Therapy1179-13142024-03-01Volume 1610511691008Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World SettingSharman Moser SApter LLivnat IGinsburg RYarden ADrori MDrizon AChodick GSiegelmann-Danieli NSarah Sharman Moser,1 Lior Apter,1,2 Idit Livnat,3 Roni Ginsburg,3 Adva Yarden,3 Michal Drori,1 Anat Drizon,1 Gabriel Chodick,1,4 Nava Siegelmann-Danieli1,4 1Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, Tel Aviv, Israel; 2Department of Health Systems Management, Ben-Gurion University of the Negev, Beer-Sheva, Israel; 3Medical Affairs, AstraZeneca, Kefar Sava, Israel; 4Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelCorrespondence: Sarah Sharman Moser, Email moser_sa@mac.org.ilBackground: In this observational study, we analyzed the treatment patterns and clinical outcomes of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) who developed brain metastases during their disease in a 2.7 million-member public health-provider in Israel.Methods: Newly diagnosed patients with mBC who initiated first-line treatment between January 2013 and June 2021 were identified. Time on treatment (ToT) and overall survival (OS) were assessed at a minimum of 6 months follow-up (cutoff: December 2021).Results: We identified a total of 61 patients: 98.4% females, median age 50 years (IQR = 44– 63), 85% invasive ductal tumors, 44% hormone receptor positive, 51% performance status 0– 1. The median duration of follow-up was 6.2 years. All patients initiated a combination treatment of trastuzumab, pertuzumab, and chemotherapy (TPC), and 72% moved to second-line treatment during the study follow-up period (82% ado-trastuzumab emtansine). The median ToT for first-line and second-line treatments were 16.9 months (95% CI = 13.9– 27.7) and 7.9 months (95% CI = 5.6– 10.9), respectively. The median overall survival (OS) was 45.5 months (95% CI = 35.4– 71.2) from the initiation of first-line treatment. When considering the timing of brain metastases, the median OS was 36.3 months (95% CI = 10.0–NR) for those diagnosed upfront (n = 15, 25%), 59.1 months (95% CI = 32.5–NR) for those diagnosed while on TPC (n = 25, 41%), and 40.8 months (95% CI = 35.4–NR) for those diagnosed at a later stage (n = 21, 34%). The median OS from brain metastases diagnosis was 25.1 months (95% CI = 17.0– 34.6).Conclusion: Patients with upfront brain involvement at the time of mBC diagnosis had shorter survival compared to those who started TPC without brain metastases. Nonetheless, the overall results from this study compare favorably with previous studies and contribute to understanding the value of traditional treatment options, which will serve as a baseline for future treatment strategies in the real-world setting.Keywords: HER2 positive, metastatic, breast cancer, observational study, real-worldhttps://www.dovepress.com/clinical-outcomes-of-patients-with-her2-positive-metastatic-breast-can-peer-reviewed-fulltext-article-BCTTher2 positivemetastaticbreast cancerobservational studyreal-world |
| spellingShingle | Sharman Moser S Apter L Livnat I Ginsburg R Yarden A Drori M Drizon A Chodick G Siegelmann-Danieli N Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting Breast Cancer: Targets and Therapy her2 positive metastatic breast cancer observational study real-world |
| title | Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting |
| title_full | Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting |
| title_fullStr | Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting |
| title_full_unstemmed | Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting |
| title_short | Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting |
| title_sort | clinical outcomes of patients with her2 positive metastatic breast cancer to the brain with first line trastuzumab pertuzumab and chemotherapy in a real world setting |
| topic | her2 positive metastatic breast cancer observational study real-world |
| url | https://www.dovepress.com/clinical-outcomes-of-patients-with-her2-positive-metastatic-breast-can-peer-reviewed-fulltext-article-BCTT |
| work_keys_str_mv | AT sharmanmosers clinicaloutcomesofpatientswithher2positivemetastaticbreastcancertothebrainwithfirstlinetrastuzumabpertuzumabandchemotherapyinarealworldsetting AT apterl clinicaloutcomesofpatientswithher2positivemetastaticbreastcancertothebrainwithfirstlinetrastuzumabpertuzumabandchemotherapyinarealworldsetting AT livnati clinicaloutcomesofpatientswithher2positivemetastaticbreastcancertothebrainwithfirstlinetrastuzumabpertuzumabandchemotherapyinarealworldsetting AT ginsburgr clinicaloutcomesofpatientswithher2positivemetastaticbreastcancertothebrainwithfirstlinetrastuzumabpertuzumabandchemotherapyinarealworldsetting AT yardena clinicaloutcomesofpatientswithher2positivemetastaticbreastcancertothebrainwithfirstlinetrastuzumabpertuzumabandchemotherapyinarealworldsetting AT drorim clinicaloutcomesofpatientswithher2positivemetastaticbreastcancertothebrainwithfirstlinetrastuzumabpertuzumabandchemotherapyinarealworldsetting AT drizona clinicaloutcomesofpatientswithher2positivemetastaticbreastcancertothebrainwithfirstlinetrastuzumabpertuzumabandchemotherapyinarealworldsetting AT chodickg clinicaloutcomesofpatientswithher2positivemetastaticbreastcancertothebrainwithfirstlinetrastuzumabpertuzumabandchemotherapyinarealworldsetting AT siegelmanndanielin clinicaloutcomesofpatientswithher2positivemetastaticbreastcancertothebrainwithfirstlinetrastuzumabpertuzumabandchemotherapyinarealworldsetting |